Frontline tyrosine kinase inhibitors in soft tissue sarcomas: a role for anlotinib?

The optimal medical treatment of chemotherapy-ineligible patients affected by advanced soft tissue sarcomas is unclear. In this population, tyrosine kinase inhibitors (TKIs) represent an appealing alternative treatment strategy. First-line use of the TKI anlotinib in chemotherapy-ineligible soft tissue sarcoma patients showed promising activity across multiple histologies.